http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
조명옥,정향미,전점이,손수경,우영자,노미영,박순옥 성인간호학회 2003 성인간호학회지 Vol.15 No.2
The purpose of this study was the development of a comprehensive nursing intervention program for the client with acute lymph stasis and stage I lymphedema. Method: The Quasi-experimental design using a non-equivalent control group was used. The subjects were 22 stroke patients with lymph stasis in the control group and 23 patients in the experimental group. The complex physical therapy of Casley-Smith was carried out to the control group for 0 hours, and comprehensive nursing intervention for the experimental group was carried out for 60 minutes. The data for this study was gathered from Feb. 2002 until June 2002 and pertains knowledge about lymphedema, self-care for managing lymphedema, and circumferences of affected limbs. Data was analyzed by mean, standard deviation, x^2-test. And t-test. Result: The changes in knowledge about lymphedema, self-care practices, and circumference of affected limbs after nursing intervention did not show significant differences between control group and experiment group. Conclusion : It can be concluded that comprehensive nursing intervention had more efficiency than complex physical therapy in the treatment of edema for stroke patients because of it’s simplicity and time saving. Thereby, the comprehensive nursing intervention program developed in this study would be a useful therapy for the clients with lymph stasis and early stage lymphedema.
조명옥,정향미,전점이,손수경,우영자,노미영,박순옥 성인간호학회 2003 성인간호학회지 Vol.15 No.3
Purpose : The purpose of this descriptive study was to gain basic data to develop a self-care protocol for the lymphedema patients. Method : The subjects of this study consisted of 115 patients with lymphedema from 8 hospitals and two community health and welfare centers in Busan and Seoul. The data was collected with questionnaire by self reporting of patients between March 2001 and December 2001. Data was analyzed by mean and percentage. Result : For self-care activities in daily life, compliance of 'use skin care preparations', 'use heat and cold', 'protect from local compression on affected limbs', 'protect from insect biting', 'use aids to protect affected limbs', 'take diuretics and take protein diet' did not reach to 50%. For self-care activities related to complex physical therapy, 28.7% of subjects complied with compression garment, 14.8% with manual lymph drainage and 13.0% with exercise, 20.0% of subjects tried to treat with acupuncture and 13.9% with heat therapy. Conclusion : From this study, it is suggested that patients need to get a self-care education with correct information about self care activities and health care professionals need to develop more convenience self-care techniques of massage and exercise.
( Ho Cheol Shin ),( Jongwon Seo ),( Byung Woog Kang ),( Joon Ho Moon ),( Yee Soo Chae ),( Soo Jung Lee ),( Yoo Jin Lee ),( Seoae Han ),( Sang Kyung Seo ),( Jong Gwang Kim ),( Sang Kyun Sohn ),( Tae In 대한내과학회 2014 The Korean Journal of Internal Medicine Vol.29 No.6
Background/Aims: This study investigated the expression of nuclear factor κB (NF-κB) and the chemokine receptor (CXCR4) in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy. Methods: Seventy patients with DLBCL and treated with rituximab-CHOP (R-CHOP) were included, and immunohistochemistry was performed to determine the expression of NF-κB (IκB kinase α, p50, and p100/p52) and CXCR4. To classify DLBCL cases as germinal center B-cell-like (GCB) and non-GCB, additional immunohistochemical expression of CD10, bcl-6, or MUM1 was used in this study. The expression was divided into two groups according to the intensity score (negative, 0 or 1+; positive, 2+ or 3+). Results: The median age of the patients was 66 years (range, 17 to 87), and 58.6% were male. Twenty-seven patients (38.6%) had stage III or IV disease at diagnosis. Twenty-three patients (32.9%) were categorized as high or high-intermediate risk according to their International Prognostic Indexs (IPIs). The overall incidence of bone marrow involvement was 5.7%. Rates of positive NF-κB and CXCR4 expression were 84.2% and 88.6%, respectively. High NF-κB expression was associated with CXCR4 expression (p = 0.002), and 56 patients (80.0%) showed coexpression. However, the expression of NF-κB or CXCR4 was not associated with overall survival and EFS. On multivariate analysis that included age, gender, performance status, stage, and the IPI, no significant association between the grade of NF-κB or CXCR4 expression and survival was observed. Conclusions: The current study suggests that the tissue expression of NF-κB and CXCR4 may not be an independent prognostic marker in DLBCL patients treated with R-CHOP.
Park, Yeon Hee,Im, Seock-Ah,Kim, Sung-Bae,Sohn, Joo Hyuk,Lee, Keun Seok,Chae, Yee Soo,Lee, Ki Hyeong,Kim, Jee Hyun,Im, Young-Hyuck,Kim, Ji-Yeon,Kim, Tae-Yong,Lee, Kyung-Hun,Ahn, Jin-Hee,Kim, Gun Min,P Elsevier 2017 European journal of cancer Vol.86 No.-
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>Paclitaxel plus gemcitabine (PG) combination chemotherapy is a preferred chemotherapeutic regimen for patients with metastatic breast cancer (MBC). Eribulin mesylate is a halichondrin non-taxane inhibitor of microtubule dynamics. A recent pooled analysis with eribulin showed improved overall survival (OS) in various MBC patient subgroups pretreated with anthracycline and taxane. Furthermore, eribulin may have less neurotoxicity than paclitaxel.</P> <P><B>Patients and methods</B></P> <P>This study was a prospective randomised phase II, open-label, two-arm, multicentre study comparing eribulin plus gemcitabine (EG) with PG chemotherapy as a first-line treatment for patients with human epidermal growth factor receptor 2-negative MBC. We hypothesised that EG chemotherapy would not be inferior to PG chemotherapy. The primary end-point was progression-free survival (PFS), which was estimated to be 70% at 6 months for each arm. The secondary end-points were as follows: OS, neuropathic scale, toxicity and clinical benefit rate.</P> <P><B>Results</B></P> <P>A total of 118 patients (median age: 50, 24–66) were enrolled between March 2015 and March 2016 and were randomly assigned to PG (<I>n</I> = <I>59</I>) or EG (<I>n</I> = <I>59</I>) chemotherapy. The mean number of metastatic sites was 3 (range 1–8). The 6-month PFS rates for both arms were 72% for EG and 73% for PG (<I>P</I> = <I>0.457</I>). There was no significant difference in OS between the two groups (not reached versus 21.2 months, <I>P</I> = <I>0.2234</I>). The median number of chemotherapy cycles for both groups was 10 for EG and 8 for PG (range 2–32). Clinical benefit rates were 44% for EG and 49% for PG. Major toxicities were neutropenia and neurotoxicity. Grade II or above neurotoxicity was more common with PG than with EG (13.6% for EG versus 45.8% for PG, <I>P</I> < <I>0.0001</I>).</P> <P><B>Conclusion</B></P> <P>EG chemotherapy had similar clinical benefits to PG chemotherapy in terms of PFS but less neurotoxicity.</P> <P><B>Trial registration</B></P> <P>KCSG BR13-11; ClinicalTrials.gov, NCT02263495.</P> <P><B>Highlights</B></P> <P> <UL> <LI> This study was a prospective randomized phase II, multicentre study comparing EG with PG for MBC patients. </LI> <LI> The 6-month PFS rates for both arms were 72% for EG and 73% for PG (<I>P</I> = 0.457). </LI> <LI> EG chemotherapy had similar clinical benefits to PG chemotherapy in terms of progression-free survival but less neurotoxicity. </LI> </UL> </P>
( Se Hyun Kim ),( Jee Hyun Kim ),( Tae Yong Kim ),( In Sil Choi ),( Yee Soo Chae ),( Sun Kyung Baek ),( Seok Yun Kang ),( In Hae Park ),( Yoon Ji Choi ),( Soo Hyeon Lee ),( Joo Hyuk Sohn ),( Yeon Hee 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: The ratio of involved to retrieved lymph nodes (LNR) is suggested as a prognostic factor in operable breast cancer. However, there are confi icting results regarding its clinical signifi cance after neoadjuvant chemotherapy. We investigated the prognostic value of LNR with a thorough evaluation of potential prognostic factors in a large cohort constructed from Health Insurance Review and Assessment Service database of Korea. Methods: This retrospective analysis is based on the data of 814 patients with clinical stage II/III breast cancer treated with four cycles of adriamycin/cyclophosphamide followed by four cycles of docetaxel before surgery. We evaluated the clinical signifi - cance of the LNR (3 categories: Low, 0-0.20 vs. Intermediate, 0.21-0.65 vs. High, 0.66 -1.00) using Kaplan-Meier method, log-rank test, and Cox proportional hazard regression model. Results: A total of 799 patients underwent breast surgery (Median age 45, range 16- 74; Mastectomy 369, Lumpectomy 380, and Others 50). Axillary lymph node dissection was performed in 704 (88.1%) patients. Pathologic complete response (pCR) was achieved in 129 (16.1%) of 799 patients (HR+/HER2-, 34/373 [9.1%]; HER2+, 45/210 [21.4%]; TNBC 50/216 [23.1%]). The mean numbers of involved LN and retrieved LN were 2.70 (range 0-42) and 13.98 (range 1-64), respectively. The mean LNR was 0.17 (Low, 574 [71.8%]; Intermediate, 170 [21.3%]; High, 55 [6.9%]). In univariate analysis, LNR was signifi cantly associated with worse relapse-free survival (3-yr RFS rate 84.8% in low vs. 66.2% in intermediate vs. 54.3% in high; P <0.0001, log-rank test). In multivariate analysis, LNR was not signifi cantly associated with recurrence after adjustment of other clinical factors (Age, histologic grade, intrinsic subtype, ypT-stage, ypN-stage, lymphatic or vascular invasion, and pCR). Conclusions: LNR is not superior to ypN-stage in predicting clinical outcome of breast cancer after neoadjuvant chemotherapy.